Phenytoin in rheumatoid arthritis

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease.
• Current RA treatments have limitations and side effects.
• Phenytoin, an anticonvulsant, has potential immunomodulatory and anti-collagenase effects.

Purpose of the Study:

• To investigate the efficacy and safety of phenytoin in patients with active rheumatoid arthritis.
• To assess the impact of phenytoin on clinical outcomes and inflammatory markers in RA.

Main Methods:

• Prospective open-label study involving 18 patients with active RA.
• Patients received phenytoin 300 mg/day for 32 weeks.
• Clinical assessments, C-reactive protein, plasma viscosity, and hemoglobin were monitored.

Main Results:

• Significant improvements in clinical assessments of rheumatoid arthritis.
• No relapse observed 8 weeks post-drug withdrawal.
• Mild side effects led to withdrawal in 2 patients.
• Serum phenytoin levels were lower than expected.

Conclusions:

• Phenytoin demonstrates potential therapeutic benefits for rheumatoid arthritis.
• Further controlled studies with higher doses are warranted to confirm efficacy and safety.
• Phenytoin's effects on the immune system and collagen metabolism may contribute to its benefits in RA.